SGMO News and Press, Sangamo Therapeutics Inc. From 10/05/22

Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...

A phase 3 trial of Pfizer ( NYSE: PFE ) and Sangamo Therapeutics ( NASDAQ: SGMO ) Therapeutics' giroctocogene fitelparvovec, a gene therapy for hemophilia A, has reopened recruitment . Dosing is expected to begin next month with all trial sites operational by t...

Summary In collaboration with stellar partners like Vertex, Crispr is aggressively expanding its robust pipeline of gene-edited medicine for various disorders. By year end, Crispr is poised to file a marketing application in Europe for exa-cel, a drug designed to treat blood disor...

Summary Shares have fallen by 30% so far in 2022. Durability and safety for the Fabry disease gene therapy program continues to look best-in-class and enrollment should accelerate due to investigator enthusiasm. Excitement is palpable for CAR-Treg programs as renal transplant ...

Sangamo Therapeutics ( NASDAQ: SGMO ) reported updated preliminary results from a phase 1/2 study of its gene therapy isaralgagene civaparvovec (ST-920) to treat Fabry disease. Fabry disease is a rare inherited disorder of glycosphingolipid (fat) metabolism due...

- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the six treated patients - The five longest treated patients exhibited elevated α-Gal A activity, ranging from nearly 3-fold to nearly 17-fold above mean normal...

Sangamo Therapeutics posted another quarter of steady results, with upside at the top line versus consensus. Ongoing clinical trial momentum is an attractive feature of the company, for those investors seeking early-stage exposure to several disease segments. Despite this, we are ...

Sangamo Therapeutics, Inc. (SGMO) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Of...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Sangamo Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

Sangamo Therapeutics press release ( NASDAQ: SGMO ): Q2 GAAP EPS of -$0.29 beats by $0.06 . Revenue of $29.38M (+5.3% Y/Y) beats by $4.75M . Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). On a GAAP basis, SGMO conti...